A case of eczematoid eruption following IL-23 inhibitor: improvement with IL-17 inhibitor switching and cyclosporine combination
Open Access
- 31 December 2024
- journal article
- Published by The Korean Society for Psoriasis in Journal of the Korean Society for Psoriasis
- Vol. 21 (2) , 79-82
Abstract
Seong Hee Choi, Gil Jae Pyo, Ki Bum Myung, Seung Hyun Cheong. Journal of the Korean Society for Psoriasis 2024;21:79-82. https://doi.org/10.23203/JKSP.2024.21.2.79Keywords
This publication has 18 references indexed in Scilit:
- Risk of Paradoxical Eczema in Patients Receiving Biologics for PsoriasisJAMA Dermatology, 2024
- Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-upJournal of the American Academy of Dermatology, 2023
- The neglected twin: Nummular eczema is a variant of atopic dermatitis with codominant TH2/TH17 immune responseJournal of Allergy and Clinical Immunology, 2023
- Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 StudyAmerican Journal of Clinical Dermatology, 2020
- Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysisJournal of the American Academy of Dermatology, 2020
- Eczematous eruption after guselkumab treatment for psoriasisJAAD Case Reports, 2019
- Selective Interleukin-23 p19 Inhibition: Another Game Changer in Psoriasis? Focus on RisankizumabDrugs, 2017
- Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trialJournal of the American Academy of Dermatology, 2015
- Use of Biologic Agents in Combination with Other Therapies for the Treatment of PsoriasisAmerican Journal of Clinical Dermatology, 2014
- Nummular Eczema2012